GT Biopharma
GTBP
55 hedge funds and large institutions have $1.02M invested in GT Biopharma in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
166% more capital inflows, than outflows
Capital inflows: $317K | Capital outflows: $119K
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
38% more funds holding
Funds holding: 40 → 55 (+15)
0.71% more ownership
Funds ownership: 5.11% → 5.83% (+0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
+$43.5K |
| 2 |
Everhart Financial Group
Dublin,
Ohio
|
+$40.6K |
| 3 |
Opal Wealth Advisors
Jericho,
New York
|
+$33.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$30.6K |
| 5 |
49 Wealth Management
Austin,
Texas
|
+$26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$30.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$18.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.2K |
| 5 |
INVST
Indianapolis,
Indiana
|
-$9.6K |
GTBP Hedge Fund Activity: Q2 2026 in Review
55 of the 8,364 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2026, worth a combined $1.02M — up 56% from $657K a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GTBP positions and 7 closed out — a net gain of 15 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $43.5K. The largest seller was Vanguard Capital Management, cutting an estimated $30.6K.
- 55 institutional investors held GT Biopharma (GTBP) as of Q2 2026, up from 40 in Q1 2026.
- Funds reported $1.02M of GT Biopharma stock for Q2 2026, up 56% quarter-over-quarter.
- 22 funds opened new GT Biopharma positions in Q2 2026 and 7 closed out, a net change of +15 holders.
- The largest GT Biopharma buyer in Q2 2026 was HRT Financial, an estimated $43.5K added.
- The largest GT Biopharma seller in Q2 2026 was Vanguard Capital Management, an estimated $30.6K sold.
Based on aggregated 13F filings for Q2 2026.